Dr. Faderl Gives an Overview of Novel Therapies for AML

Video

In Partnership With:

Stefan Faderl, MD, chief, Leukemia Division, John Theurer Cancer Center, gives an overview of novel therapies for the treatment of patients with acute myeloid leukemia (AML).

Stefan Faderl, MD, chief, Leukemia Division, John Theurer Cancer Center, gives an overview of novel therapies for the treatment of patients with acute myeloid leukemia (AML).

Faderl believes that immunotherapies represent the area that will see the greatest expansion in hematologic malignancies. There has been much activity in FLT3-positive AMLs with novel inhibitors in combination with standard chemotherapies, though there is not much data available yet. Novel leukemia stem cell markers are interesting on a conceptual basis, though they may or may not hold promise, Faderl says.

Faderl says there is not a specific novel therapy that is a particular highlight.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD